Analyzing Zhengye Biotechnology (NASDAQ:ZYBT) & InMed Pharmaceuticals (NASDAQ:INM)

Zhengye Biotechnology (NASDAQ:ZYBT) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Zhengye Biotechnology and InMed Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64 million	4.93	-$9.98 million	N/A	N/A
InMed Pharmaceuticals	$4.94 million	0.92	-$8.16 million	($2.89)	-0.48

InMed Pharmaceuticals has lower revenue, but higher earnings than Zhengye Biotechnology.

Risk and Volatility

Zhengye Biotechnology has a beta of -2.72, meaning that its share price is 372% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Zhengye Biotechnology and InMed Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1	0	0	0	1.00
InMed Pharmaceuticals	1	0	0	0	1.00

Insider and Institutional Ownership

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zhengye Biotechnology and InMed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Summary

Zhengye Biotechnology beats InMed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.